Bernard P Arulanandam
Overview
Explore the profile of Bernard P Arulanandam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
1767
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jeffreys S, Tompkins M, Aki J, Papp S, Chambers J, Guentzel M, et al.
Vaccines (Basel)
. 2024 Apr;
12(4).
PMID: 38675740
Multi-drug-resistant (MDR) is an opportunistic pathogen associated with hospital-acquired infections. Due to its environmental persistence, virulence, and limited treatment options, this organism causes both increased patient mortality and incurred healthcare...
2.
Jeffreys S, Chambers J, Yu J, Hung C, Forsthuber T, Arulanandam B
Front Immunol
. 2022 Dec;
13:1070424.
PMID: 36466845
is a nosocomic opportunistic Gram-negative bacteria known for its extensive drug-resistant phenotype. hospital-acquired infections are major contributors to increased costs and mortality observed during the COVID-19 pandemic. With few effective...
3.
Mahjabeen F, Yu J, Chambers J, Gupta R, Arulanandam B
Int J Microbiol
. 2022 May;
2022:6082140.
PMID: 35498397
Fetuin-A is an acute phase glycoprotein shown to counter in a regulatory manner proinflammatory cytokine production to maintain homeostasis during inflammation. We report here that in wild-type mice 12 days...
4.
Goyins K, Yu J, Papp S, Beddard R, Murthy A, Chambers J, et al.
Exp Biol Med (Maywood)
. 2022 Apr;
247(12):1055-1060.
PMID: 35369776
Understanding the immune response to SARS-CoV-2 is important for development of effective diagnostics and vaccines. We report here a broad antibody response to SARS-CoV-2 spike protein receptor binding domain (RBD)...
5.
Shrihari S, May H, Yu J, Papp S, Chambers J, Guentzel M, et al.
Exp Biol Med (Maywood)
. 2021 Oct;
247(3):282-288.
PMID: 34713732
is a Gram-negative bacterium responsible for many hospital-acquired infections including ventilator-associated pneumonia and sepsis. We have previously identified thioredoxin A protein (TrxA) as a virulence factor with a multitude of...
6.
Smiley-Moreno E, Smith D, Yu J, Cao P, Arulanandam B, Chambers J
PLoS One
. 2021 Jun;
16(6):e0252377.
PMID: 34077475
Genomic sequence analysis of Acinetobacter baumannii revealed the presence of a putative Acid Phosphatase (AcpA; EC 3.1.3.2). A plasmid construct was made, and recombinant protein (rAcpA) was expressed in E....
7.
Keck J, Chambers J, Yu J, Cheng X, Christenson L, Guentzel M, et al.
Front Cell Infect Microbiol
. 2021 Apr;
11:638058.
PMID: 33928045
Previously, our laboratory established the role of small, noncoding RNA species, microRNA (miRNA) including miR-135a in anti-chlamydial immunity in infected hosts. We report here chlamydial infection results in decreased miR-135a...
8.
Chambers J, Yu J, Valdes J, Arulanandam B
J Pathog
. 2020 Dec;
2020:9238696.
PMID: 33299610
Viruses are obligate intracellular parasites, and host cell entry is the first step in the viral life cycle. The SARS-CoV-2 (COVID-19) entry process into susceptible host tissue cells is complex...
9.
Keck J, Chambers J, Kancharla A, Bashir D, Henley L, Schenkel K, et al.
Microbes Infect
. 2020 Feb;
22(8):360-365.
PMID: 32084556
Our laboratory has investigated the role of an evolutionarily conserved RNA species called microRNAs (miRs) in regulation of anti-chlamydial protective immunity. MiRs including miR-155 expressed in specific immune effector cells...
10.
May H, Yu J, Shrihari S, Seshu J, Klose K, Cap A, et al.
Front Microbiol
. 2020 Jan;
10:2849.
PMID: 31921031
, a Gram-negative coccobacillus, has become a prevalent nosocomial health threat affecting the majority of hospitals both in the U.S. and around the globe. Microbial cell surface hydrophobicity (CSH) has...